Allt inom Report

The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quality of life for patients.

Very interesting data from the latest study and successful share issue.